These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 33909100)

  • 21. Association between male infertility and prostate cancer: a systematic review and meta-analysis.
    Laukhtina E; Mori K; Pradere B; Shariat SF
    Curr Opin Urol; 2021 Jul; 31(4):346-353. PubMed ID: 33965979
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Jiao D; Zhou X; Yao Y; Chen J; Lei Q; Ren J; Han X
    Am J Cancer Res; 2021; 11(4):1321-1334. PubMed ID: 33948360
    [No Abstract]   [Full Text] [Related]  

  • 23. The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation.
    Kadena S; Urabe F; Iwatani K; Suzuki H; Imai Y; Tashiro K; Tsuzuki S; Honda M; Koike Y; Shimomura T; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
    Int J Clin Oncol; 2023 Aug; 28(8):1092-1100. PubMed ID: 37227547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer.
    Rosenbrock J; Baues C; Kreis M; Fouassi R; Celik E; Paffenholz P; Pfister D; Heidenreich A; Marnitz S
    Strahlenther Onkol; 2023 Jun; 199(6):574-584. PubMed ID: 36930248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
    Imai Y; Urabe F; Iwatani K; Nakazono M; Tashiro K; Honda M; Aoki M; Sato S; Takahashi H; Miki K; Kimura T
    Int J Clin Oncol; 2023 May; 28(5):698-706. PubMed ID: 36814038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
    Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
    Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer.
    Gogola S; Rejzer M; Bahmad HF; Alloush F; Omarzai Y; Poppiti R
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer.
    Mori K; Sasaki H; Tsutsumi Y; Sato S; Takiguchi Y; Saito S; Nishi E; Ishii G; Yamamoto T; Koike Y; Miki J; Shimomura T; Kimura T; Miki K; Shariat SF; Takahashi H; Aoki M; Egawa S
    Strahlenther Onkol; 2021 Nov; 197(11):976-985. PubMed ID: 33909100
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Smile TD; Tom MC; Halima A; Ciezki JP; Reddy CA; Stephans KL; Mian OY; Zhang RX; Klein EA; Campbell S; Ulchaker J; Angermeier K K; Tendulkar RD
    Brachytherapy; 2022; 21(1):85-93. PubMed ID: 34656435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.
    Ishiyama H; Satoh T; Kitano M; Tabata K; Komori S; Ikeda M; Soda I; Kurosaka S; Sekiguchi A; Kimura M; Kawakami S; Iwamura M; Hayakawa K
    J Radiat Res; 2014 May; 55(3):509-17. PubMed ID: 24222312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
    Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
    Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
    Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
    Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Kasahara T; Ishizaki F; Kazama A; Yuki E; Yamana K; Maruyama R; Oshikane T; Kaidu M; Aoyama H; Bilim V; Nishiyama T; Tomita Y
    Int J Urol; 2020 Sep; 27(9):800-806. PubMed ID: 32633027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
    Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
    Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Dose Rate Brachytherapy in High-Risk Localised Disease - Why Do Anything Else?
    Morton GC; Alrashidi SM
    Clin Oncol (R Coll Radiol); 2020 Mar; 32(3):163-169. PubMed ID: 31791573
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.